Corcept Therapeutics Incorporated
Financials
Valuation Metrics
Corcept Therapeutics Incorporated's Market Cap is $11.84B. At end of 2025 it was $3.61B. Ranked #807 of 3,121 in US market (top 26%), #253 of 1,463 on NASDAQ (top 17%), #39 of 266 in Pharmaceuticals, Biotechnology & Life Sciences (top 15%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $11.84B | US#807/3,121 Sec#39/266 |
| Revenue | $831M | US#1,984/3,121 Sec#58/266 |
| Net Income | $55M | US#1,851/3,121 Sec#61/266 |
| Total Assets | $889M | US#2,532/3,121 Sec#112/266 |
| Net Assets | $706M | US#2,004/3,121 Sec#86/266 |
| Employees | 730 | US#2,117/3,121 Sec#68/266 |
| Value | ||
| P/E | 215.68x | US#2,183/3,121 Sec#72/266 |
| P/B | 16.78x | US#2,767/3,121 Sec#215/266 |
| P/S | 14.25x | US#2,791/3,121 Sec#131/266 |
| EV/EBITDA | 407.73x | US#2,509/3,121 Sec#86/266 |
| FCF Yield | 0.90% | US#2,199/3,121 Sec#78/266 |
| Profitability | ||
| ROE | 7.78% | US#1,617/3,121 Sec#53/266 |
| ROA | 6.18% | US#891/3,121 Sec#48/266 |
| Op. Margin | 0.77% | US#2,311/3,121 Sec#79/266 |
| Revenue Growth | 16.02% | US#861/3,121 Sec#82/266 |
| Earnings Growth | -58.66% | US#1,771/3,121 Sec#47/266 |
| Financial Health | ||
| Debt Ratio | 25.92% | US#290/3,121 Sec#95/266 |
| Total Debt | $9M | US#2,842/3,121 Sec#201/266 |
| FCF | $107M | US#1,710/3,121 Sec#60/266 |
| Cash | $111M | US#2,167/3,121 Sec#164/266 |
| Current Ratio | 2.86x | US#844/3,121 Sec#198/266 |
| Net Debt/EBITDA | -3.53x | US#94/3,121 Sec#6/266 |
| Performance | ||
| 1Y Return | 38.21% | US#543/3,121 Sec#108/266 |
| 1M Return | -7.33% | US#1,339/3,121 Sec#122/266 |
| From 52W High | -12.73% | US#636/3,121 Sec#47/266 |
| 1Y MDD | -64.40% | US#2,861/3,121 Sec#223/266 |
| Trading | ||
| Volume | 13,026,757 shares | US#1,552/3,121 Sec#170/266 |
| Trading Value | $1.46B | US#859/3,121 Sec#58/266 |
| Per Share | ||
| EPS | $0.51 | US#1,884/3,121 Sec#57/266 |
| BPS | $6.57 | US#2,139/3,121 Sec#108/266 |
Company Info
Corcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. The company offers Korlym, an oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. It also develops relacorilant, a selective cortisol modulator for patients with hypercortisolism; a selective cortisol modulator miricorilant, which is in Phase 1b trial for metabolic dysfunction-associated steatohepatitis; and a portfolio of proprietary selective cortisol modulators, such as relacorilant, nenocorilant, miricorilant, and dazucorilant for the treatment of Lou Gehrig's disease. The company was incorporated in 1998 and is headquartered in Redwood City, California.